Much up in the air. Which is understandable, under the current circumstances. Interesting to me,
RCPI now giving themselves until end of year to file for European IND?...originally, this was by end of Q3. So, is RCPI keeping its options open since the FDA has not provided approval yet for first condition treatment phase 1? That would be my guess. Perhaps you go for Osteoarthritis now in Europe?
Thoughts?
And, what is the hope for strategy on neutraceutical by end of year?...are they just buying time, or is this still a possibility for pursuit in Europe...or somehow still here in US?
Thoughts?
